SEC 13F Intelligence

Highvista Strategies LLC / AKRO

Highvista Strategies LLC’s Akero Therapeutics Inc Com Position

Does Highvista Strategies LLC own Akero Therapeutics Inc Com (AKRO)? Not currently — the last reported position was 110.1K shares worth $5M in Q3 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$5M
Q3 2025
Shares
110.1K
% of Portfolio
+1.28%
Quarters Held
8
position exited

Position History AKRO

Reported value by quarter
Q4 ’20: $716,000Q4 ’20Q4 ’22: $1MQ4 ’22Q1 ’23: $712,746Q1 ’23Q3 ’23: $577,017Q3 ’23Q4 ’24: $348,557Q4 ’24Q1 ’25: $974,232Q1 ’25Q2 ’25: $3MQ2 ’25Q3 ’25: $5MQ3 ’25filingsflow.com
QuarterSharesValue% of Portfolio
Q3 2025110.1K$5M+1.28%
Q2 202560.0K$3M+1.18%
Q1 202524.1K$974,232+0.38%
Q4 202412.5K$348,557+0.13%
Q3 202311.4K$577,017+0.27%
Q1 202318.6K$712,746+0.58%
Q4 202218.6K$1M+0.61%
Q4 202027.7K$716,000+0.46%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Highvista Strategies LLC’s full portfolio or all institutional holders of AKRO.